PROCISE cLC Sequencing System 2 Cart w/PC

描述（由申请人提供）：申请购买Applied Biosystems PROCISE (r) cLC测序系统的支持。应用生物系统公司是蛋白质测序仪的唯一制造商。PROCISE是最先进的自动化Edman蛋白测序仪器。该仪器将取代15年前购买的过时的477A型音序器。PROCISE的灵敏度大约是477A的100倍，477A目前是布莱根妇女医院（BWH）生物聚合物实验室（BPL）核心蛋白质化学设施中唯一的蛋白质测序仪。自1984年以来，BPL一直为BWH、哈佛医学院及其附属教学医院以及美国和国外其他机构的用户提供标准测序服务。此外，BPL是放射性序列分析的世界中心，这是由相对较少的实验室完成的。这种技术使用pre。事实上放射性标记的蛋白质样品，以确定特定氨基酸的位置，通过周期性的放射性检测，在每个周期的艾德曼化学。这种高度敏感的（原子摩尔）方法允许对不适合序列分析或质谱表征的样品进行序列测定。12个nih资助的项目组成了我们的“主要用户组”。预计的测序样本数量将使新仪器持续运行，并且需要放射性测序功能，因此购买PROCISE仪器是必要的，以实现NIH资助用户组的目标。这些目标涉及与重要人类疾病相关的关键问题，包括阿尔茨海默病、帕金森病、多发性硬化症和骨质疏松症。除了提供研究这些疾病的手段外，PROCISE灵敏度的提高将为研究低丰度蛋白质的研究人员开辟新的机会，这些研究人员由于过时的477仪器的灵敏度相对较低而无法将测序方法应用于他们的项目。重要的是，正如在引进新的或改进的仪器之后无数次发生的那样，我们完全期望PROCISE仪器的可用性将使人类疾病的理解和治疗取得不可预见的进展。

DESCRIPTION (provided by applicant): Support is requested for the purchase of an Applied Biosystems PROCISE (r) cLC Sequencing System. Applied Biosystems is the only manufacturer of protein sequenators. The PROCISE is a state-of-the-art instrument for automated Edman protein sequencing. The instrument will replace an obsolete Model 477A sequenator that originally was purchased 15 years ago. The PROCISE is approximately 100-fold more sensitive than the 477A, which is currently the sole protein sequenator in a core protein chemistry facility, the Biopolymer Laboratory (BPL), at Brigham and Women's Hospital (BWH). Since 1984, the BPL has provided standard sequencing services to users at BWH, Harvard Medical School and its affiliated teaching hospitals, and other institutions in the US and in foreign countries. In addition, the BPL is a world center for radiosequence analysis, which is done by relatively few laboratories. This technique uses pre.facto radiolabeled protein samples to identify positions of specific amino acids through the periodicity of radioactivity detected in each cycle of the Edman chemistry. This highly sensitive (attomolar) method allows sequence determination of samples not otherwise amenable to sequence analysis or to mass spectrometric characterization. Twelve NIH-funded projects comprise our "major user group." The number of projected sequencing samples, which will keep the new instrument running continuously, and the need for radiosequencing capabilities, make purchase of the PROCISE instrument necessary to achieve the aims of the NIH grants funding the user group. These aims address key questions related to important human diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and osteoporosis. In addition to providing the means to study these diseases, the improved sensitivity of the PROCISE will open up new opportunities for researchers studying low abundance proteins and who were precluded from applying sequencing methods to their projects due to the relatively low sensitivity of the obsolete 477 instrument. Importantly, as has happened countless times following the introduction of new or improved instrumentation, we fully expect that unforeseen advances in the understanding and treatment of human disease will be enabled by the availability of the PROCISE instrument.